Project Grant R03AI202471
Award Date 8/14/26
Completion Date 7/31/28
Dollars Obligated $156K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $800,557 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host defense. The funded research identifies mechanisms by which diverse S. aureus strains, including toxigenic and non-toxigenic variants, activate inflammasome regulatory proteins in immune cells....
- The National Institute of Allergy and Infectious Diseases awarded the University of Nebraska $137,005 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host immune and metabolic determinants of Staphylococcus aureus persister survival. The research examines how S. aureus persister cells—dormant bacterial populations that survive antibiotic therapy—interact with the host immune system and evade antimicrobial responses. Aim 1 defines...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $149,190 on January 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support Project Grant F31AI191794, a doctoral fellowship examining mechanisms of antibiotic persistence in a mouse model of systemic infection. The research develops and uses a mouse model of systemic bacterial infection to study how phenotypically distinct bacterial subpopulations survive...
- The National Institute of Allergy and Infectious Diseases awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $586,920 in project grant funding on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will conduct research on pyruvate acquisition by Staphylococcus aureus in intracellular environments. The work characterizes the regulation and physiological roles of bacterial...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $664,076 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R01AI196089) to investigate the molecular mechanisms by which Staphylococcus aureus alpha-toxin impairs antigen-specific T cell response and adaptive immunity. The research examines how S. aureus alpha-toxin (HLA) functions as a virulence factor and potential vaccine target. The work...
- The National Institute of Allergy and Infectious Diseases awarded $488,238 to the University of Florida on August 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the impacts of Staphylococcus aureus nitric oxide synthase on bacterial survival and physiological adaptation in host environments. The research addresses how bacterial nitric oxide synthase (BNOS) regulates S. aureus metabolism, stress resistance, and virulence factor expression....
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $195,640 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research integrating genomic and clinical approaches to define and prevent cefiderocol resistance in carbapenem-resistant organisms. The research addresses gaps in understanding cefiderocol resistance mechanisms and clinical use in carbapenem-resistant organisms, which cause severe...
- The National Institute of Allergy and Infectious Diseases awarded Rutgers, The State University $421,889 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cytosolic copper ion accumulation and proteome integrity in Staphylococcus aureus. The project addresses antimicrobial resistance in S. aureus and other ESKAPE pathogens by examining how copper ions toxify bacteria through protein misfolding and aggregation. The research characterizes...
- The National Institute of Allergy and Infectious Diseases awarded a cooperative agreement totaling $634,247 to the University of Maryland, Baltimore on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the role of penicillin-binding protein 4 (PBP4) in mediating antibiotic resistance and pathogenesis of Staphylococcus aureus. The research investigates how PBP4-mediated mutations enable high-level, broad-spectrum β-lactam...
- The National Institute of Allergy and Infectious Diseases awarded President and Fellows of Harvard College $253,500 on May 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how a novel uridyltransferase enzyme named NAGU coordinates peptidoglycan cell wall synthesis with turgor pressure regulation in Staphylococcus aureus. Research will combine genetics, biochemistry, cell biology, and metabolomics to characterize NAGU's cellular roles and...